Abstract
The planning and execution of clinical trials utilizing response-adaptive allocation involves complexities beyond those encountered in the planning and execution of more traditional trial designs. How the adaptive design will optimize the drug development process must be clearly defined; an appropriate endpoint must be selected to drive the adaptive design engine; and steps must be taken to ensure that the data required for adaptive decision making will be available in a timely fashion during the trial. Trial simulations are essential during the planning stage to develop appropriate decision rules and the response-adaptive allocation algorithm, Structures such as data monitoring committees and independent statistical centers help to ensure the validity and integrity of the trial while facilitating decision making during the trial.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dragalin V. Designing, monitoring, and modifying an adaptive trial. Am Pharm Outsourcing 2008;9(5):12–16.
Rosenbergcr WF, Lachin JM. The use of response-adaptive designs in clinical trials. Control Clin Trials. 1993;14:471–484.
Gaydos B, Krams M, Perevozskaya I, et al. Adaptive dose-response studies. Drug Inf J 2006;40:451–461.
Bornkamp B, Bretz F. Dmitrienko A, et al. White paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies: innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat 2007;17:965–995.
Dragalin V, Fedorov V, Adaptive designs for dose-finding based on efficacy-toxicity response. J Slat Plan Infer. 2006;136:1800–1823.
Grieve AP, Krams M. ASTIN: A Bayesian adaptive dose-response trial in acute stroke. Clin Trials. 2005;2:340–351.
Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J 2006;40:437–444.
Gallo P. Confidentiality and trial integrity issues for adaptive designs. Drug Inf J. 2006;40:445–449
Enas G, Anderson K, Bedding A, et al. Global harmonization of standards for adaptive clinical trial designs. Reg Focus. 2008;13(8):8–17.
Chuang-Stein C, Brelz F, Komiyama O, Quinlan J. Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs. Reg Focus. 2009;14(4):36–42.
Gaydos B, Anderson K. Berry DA, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J. 2009;43:539–556.
Galbraith S, Marschner IC. Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes. Stat Med 2003;22:1787–1805.
Marschner IC, Becker SL. Interim monitoring of clinical trials based on long-term binary end-points. Stat Med 2001;20:177–192.
Krams M, Sharma M, Dragalin V, et al. Adaptive approaches in clinical drug development: opportunities and challenges in design and implementation. Pharm Med 2009;23(3):139–148.
Fardipour P, Littman G, Burns D, et al. Planning and executing response-adaptive learn-phase clinical trials: 2. Case studies. Drug Inf J 2009;43:725–734.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fardipour, P., Littman, G., Burns, D.D. et al. Planning and Executing Response-Adaptive Learn-Phase Clinical Trials: 1. The Process. Ther Innov Regul Sci 43, 713–723 (2009). https://doi.org/10.1177/009286150904300609
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150904300609